Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dolby Laboratories (DLB) Asset Writedowns and Impairment (2016 - 2025)

Dolby Laboratories (DLB) has disclosed Asset Writedowns and Impairment for 17 consecutive years, with $792000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 8.49% year-over-year to $792000.0, compared with a TTM value of $2.5 million through Dec 2025, up 334.09%, and an annual FY2025 reading of $2.4 million, up 207.89% over the prior year.
  • Asset Writedowns and Impairment was $792000.0 for Q4 2025 at Dolby Laboratories, up from -$148000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.7 million in Q2 2023 and bottomed at -$2.2 million in Q3 2022.
  • Average Asset Writedowns and Impairment over 5 years is $77200.0, with a median of $346500.0 recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment crashed 482.01% in 2022, then surged 1132.34% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at $1.6 million in 2021, then tumbled by 166.07% to -$1.0 million in 2022, then tumbled by 103.98% to -$2.1 million in 2023, then soared by 134.75% to $730000.0 in 2024, then rose by 8.49% to $792000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for DLB at $792000.0 in Q4 2025, -$148000.0 in Q3 2025, and $615000.0 in Q2 2025.